Lead Product(s) : Benfotiamine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : National Institutes of Health
Deal Size : $45.0 million
Deal Type : Funding
Details : The follow-up trial will expand on previous work completed at BNI, suggesting that high levels of benfotiamine significantly slowed the rate of functional decline in participants with mild cognitive impairment or early AD.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 07, 2022
Lead Product(s) : Benfotiamine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : National Institutes of Health
Deal Size : $45.0 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?
Reset All
